Tamoxifen in clomiphene-resistant hypothalamic anovulation

Area of Science:

• Reproductive Endocrinology
• Pharmacology

Background:

• Hypothalamic anovulation is a common cause of infertility.
• Clomiphene citrate is a first-line treatment, but some patients are resistant.
• Alternative ovulation induction agents are needed.

Purpose of the Study:

• To evaluate tamoxifen's efficacy in inducing ovulation in clomiphene-resistant patients.
• To assess tamoxifen's effectiveness in previously untreated patients with hypothalamic anovulation.

Main Methods:

• Seventeen clomiphene-resistant patients received tamoxifen (10 mg/day, cycle days 5-9) for two cycles.
• Forty-five treatment-naive patients with hypothalamic anovulation received tamoxifen (10 mg/day, cycle days 5-9).
• Ovulation was monitored via ultrasound and serum estradiol levels.

Main Results:

• Tamoxifen failed to induce ovulation in 15 of 17 clomiphene-resistant patients.
• One of the two responsive clomiphene-resistant patients conceived after hCG administration.
• Tamoxifen induced ovulation in 84% of cycles in treatment-naive patients.
• Improved cervical mucus was observed with tamoxifen compared to clomiphene.

Conclusions:

• Tamoxifen is not effective for clomiphene-resistant hypothalamic anovulation.
• Tamoxifen shows promise for inducing ovulation in treatment-naive patients with hypothalamic anovulation.
• Tamoxifen may offer advantages over clomiphene in certain patient populations.